We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
A car-sharing platform for drivers to receive an extra income by allowing the local community to drive their cars instead of leaving it idle and unused. Hiyacar has a acquired an exclusive insurance product with AXA and already has more than 2,000 cars enrolled, with the majority located in London and surrounding urban areas with the intention of expanding further in the future.
days to go: Expired investment: £1,431,885
Tethered Drones Systems Limited (TDS) builds and develops autonomous tethered drones for use in surveillance and communications scenarios. Its product, Tethered UAV, exhibits a flight duration of 24 hours or more with secure communication via a tether. The platform can carry a range of payloads to meet client needs. The company asserts that the product has multiple uses for broadcasters such as telecasting outdoor sporting events. The UAV's blue light services, including search and rescue, holds prominence in high-risk maintenance inspections for oil and gas platforms and wind farms – both on and offshore. The company will use the investment to grow its business across different verticals.
days to go: Expired investment: £73,125
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
Adande Aircell®Limited (AAL) is an airflow management system designed to fit into the current cabinet designs to minimise and reduce energy usage, improve temperature stability, and stop cold air falling out. It significantly improves the efficiency and performance of the refrigerator. The Aircell® technology is protected by a bunch of series of patents filed internationally and in the UK. With the proceeds, the company will manufacture and sell the whole unit and create a secondary stream to ensure that the company can demonstrate the technology through trade shows and in-store demonstrations.
days to go: Expired investment: Withheld
Alvant is a British advanced materials technology group that specialises in the design, development, testing and manufacture of Aluminium Metal Matrix Composite materials and components (AMCs). These components are demanded the engineering applications across a wide range of industry sectors. Till now, they have invested £10 million for the development, prototyping & testing AMC materials with several projects secured with distinguished clients such as Ford & Safran. Alvant has seen new advances in current customer projects and applications. Space - Tesla, Design for Demise(D4D), Bauer Hockey are some examples. With the proceeds, the company will accelerate commercialisation and growth at the rate its customers are presently demanding.
days to go: Expired investment: Withheld
A purpose-focused digital nutrition brand with a goal to enhance amino acids' impact worldwide, aiming to transform human health and performance; Having sold over 10,000 units to customers across 30+ countries, generating a monthly revenue of £27,000; Successfully raised £270,000 in funding, achieving overfunding with EIS approval and activating a £300,000 growth loan through FSE Group, further supported by the founder's personal guarantee of £150,000 due to strong confidence in success. Experience the next level of amino acid products with a delightful twist - No more struggling with water binding and bitterness. Through innovative methods, we've introduced the market's first enjoyable amino acid drink.
days to go: Expired investment: £275,000
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Arca have introduced new tools for property risk management and created a marketplace to trade portfolio risks to match buyers and sellers of financial products connected to the performance of real estate. They are opening up the concept of short term property market risk management for property portfolio managers.  
days to go: Expired investment: £575,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph